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Abstract
Eating disorders and substance use disorders frequently co-occur. Twin studies reveal
shared genetic variance between liabilities to eating disorders and substance use,
with the strongest associations between symptoms of bulimia nervosa and problem
alcohol use (genetic correlation [rg], twin-based = 0.23-0.53). We estimated the
genetic correlation between eating disorder and substance use and disorder pheno-
types using data from genome-wide association studies (GWAS). Four eating disorder
phenotypes (anorexia nervosa [AN], AN with binge eating, AN without binge eating,
and a bulimia nervosa factor score), and eight substance-use-related phenotypes
(drinks per week, alcohol use disorder [AUD], smoking initiation, current smoking, cig-
arettes per day, nicotine dependence, cannabis initiation, and cannabis use disorder)
from eight studies were included. Significant genetic correlations were adjusted for
variants associated with major depressive disorder and schizophrenia. Total study
sample sizes per phenotype ranged from ~2400 to ~537 000 individuals. We used
linkage disequilibrium score regression to calculate single nucleotide polymorphism-
based genetic correlations between eating disorder- and substance-use-related phe-
notypes. Significant positive genetic associations emerged between AUD and AN (rg
= 0.18; false discovery rate q = 0.0006), cannabis initiation and AN (rg = 0.23; q <
0.0001), and cannabis initiation and AN with binge eating (rg = 0.27; q = 0.0016). Con-
versely, significant negative genetic correlations were observed between three non-
diagnostic smoking phenotypes (smoking initiation, current smoking, and cigarettes
per day) and AN without binge eating (rgs = −0.19 to −0.23; qs < 0.04). The genetic
correlation between AUD and AN was no longer significant after co-varying for major
depressive disorder loci. The patterns of association between eating disorder- and
substance-use-related phenotypes highlights the potentially complex and substance-
specific relationships among these behaviors.
K E YWORD S
eating disorders, genetic correlation, substance use
1 | INTRODUCTION
Well-established phenotypic associations exist between eating disor-
der and substance use phenotypes, with evidence for specific rela-
tions between particular types of eating disorders and substance use
disorders. The prevalence of an alcohol use disorder (AUD) is greater
among individuals with bulimia nervosa and binge-eating disorder
than individuals with anorexia nervosa (AN) or healthy controls.1,2
Similarly, individuals with bulimia nervosa or binge-eating disorder are
at increased risk for smoking, nicotine dependence,3,4 and cannabis
use,4,5 compared with individuals with AN or healthy controls, though
these results are not consistent.1 Importantly, women with the binge-
eating/purging subtype of AN report a higher prevalence of AUD,
smoking, nicotine dependence, and cannabis use than women with
the restricting subtype of AN.1,5,6 Thus, binge eating—a trans-
diagnostic symptom defined as eating a large amount of food in a
short period of time while experiencing loss of control—may be a key
component of the observed association.
However, prior research has only partially addressed whether
binge eating is the critical eating disorder symptom in the comorbidity,
especially across different milestones of substance use (ie, initiation
through substance use disorder) and across a variety of substances
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(ie, alcohol, nicotine, and cannabis). Elucidating shared sources for
these associations is crucial because of the increased morbidity and
mortality associated with comorbid presentations7,8 and because
improvements in one disorder may exacerbate (or weaken) symptoms
of the other disorder.9 Refining our understanding of these associa-
tions could improve prevention and treatment approaches for these
debilitating disorders, their comorbidity, and their sequelae.
Accumulating findings from twin studies implicate shared genetic
factors between eating disorder- and substance-use-related pheno-
types. The strongest reported association is between bulimia nervosa
symptoms (including binge eating) and problem alcohol use, with a
genetic correlation (rg) ranging from 0.23 to 0.53.
10 Although there
has been less focus on genetic associations between bulimia nervosa
symptoms and regular smoking and bulimia nervosa symptoms and
illicit drug use disorder, twin-based rgs of 0.35 and approximately
0.38, respectively, have been reported.11,12 Limited information exists
regarding whether less problematic aspects of substance use exhibit a
significant rg with eating disorder phenotypes. The impact of genetic
factors influencing this comorbidity may significantly increase once an
individual has progressed to problematic alcohol use, as genetic
effects are more prominent in problem substance use, such as abuse
and dependence, than with the initiation and general use of sub-
stances.13-16 No study has comprehensively examined a range of eat-
ing disorder- and substance-use-related phenotypes to determine
whether the rg varies with different aspects of substance use and
whether the rg varies depending on the eating disorder and substance
examined.
Recent advances in genomic methods allow for an assessment of
rg using existing genome-wide association study (GWAS) summary
statistics. Unlike twin studies, these genome-wide methods allow for
use of unrelated cases and controls, typically yielding sample sizes in
the tens to hundreds of thousands. One such method, linkage disequi-
librium score regression (LDSC),17,18 estimates single nucleotide poly-
morphism (SNP)-based heritability and rg between phenotypes. Of
particular relevance to low prevalence phenotypes, such as AN, esti-
mation of SNP-based rg does not require both phenotypes to be mea-
sured in the same individual; thus, independent studies assessing only
one phenotype can be jointly examined.
The current study estimated SNP-based genetic correlations (rgs)
between eating disorder- and substance-use-related phenotypes
based upon summary statistics from the largest published eating dis-
order GWAS and existing GWAS encompassing a range of substance-
use-related phenotypes (ie, alcohol, nicotine, and cannabis), using
robust data from twin studies to shape our three hypotheses. First,
we hypothesized that the strongest SNP-based rg would be between
eating disorder phenotypes that have binge eating as a core symptom
and alcohol use phenotypes, rather than between eating disorder phe-
notypes and nicotine and cannabis use-related phenotypes.10 Second,
we hypothesized that for binge eating-related phenotypes, the SNP-
based rg would be higher when assessing AUD than typical alcohol
consumption,10 because we expected that two problem behaviors are
more likely to share genetic risk than a problem behavior (eg, binge
eating) and a normative pattern (eg, alcohol consumption). Because
we have less information from twin studies about genetic associations
between liabilities to eating disorders and tobacco (nicotine) and can-
nabis use-related phenotypes, we do not forward specific hypotheses
for these substances. Finally, prior studies document robust genetic
associations for major depressive disorder and schizophrenia with
both eating disorders and substance-use-related phenotypes.19-21 We
hypothesized that rgs between eating disorders and substance use
and disorder would be attenuated when accounting for variants asso-
ciated with major depressive disorder and schizophrenia. Findings
from this study will yield important information about the role of
genetics in this clinically challenging pattern of comorbidity.22
2 | METHOD
2.1 | Participants
We included summary statistics from two existing GWAS of eating
disorder phenotypes where participants were primarily of European
ancestry21,23 and data from individuals of European ancestry from six
existing GWAS of substance-use-related phenotypes.19,20,24-27 The
eating disorder phenotypes (Table 1) included a diagnosis of AN
(which was further parsed into AN with binge eating or AN without
binge eating) and a bulimia nervosa factor score derived from the
Eating Disorder Examination,28 a well-established structured clinical
interview for eating disorders. We did not examine bulimia nervosa or
binge-eating disorder because there are currently no published GWAS
for either disorder; thus, the bulimia nervosa factor score represents
the closest to a GWAS of bulimia nervosa available. Substance-use-
related phenotypes ranged from typical use (eg, drinks per week,
smoking initiation, and cannabis initiation) to substance use disorder
(ie, AUD, nicotine dependence, and cannabis use disorder). Sample
sizes for the phenotypes ranged from 2442 (bulimia nervosa factor
score) to 537 349 (drinks per week) individuals. Table 2 provides indi-
vidual study details.
2.2 | Statistical analysis
We used LDSC17,18 to evaluate SNP-based genetic correlations (rg)
between samples. This method uses the linkage disequilibrium
(LD) structure of the genome to estimate the distribution of effect
sizes for individual SNPs as a function of their LD score. Under a
polygenic model, causal SNPs are likely to be overrepresented in
higher LD score bins (ie, including additional SNPs in high LD), such
that associations with SNPs in these LD bins will make stronger
contributions to the phenotypic variation under study. This polygenic
distribution of effect sizes across LD score bins provides an estimate
of SNP-based heritability, that is, the proportion of phenotypic vari-
ance that is attributable to the aggregate effects of genome-wide
SNPs. The correlation of effect sizes across LD bins between two phe-
notypes then provides an estimate of SNP-based rg.
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Genetic correlations range from −1 to +1, where the sign indi-
cates that the same genetic factors are contributing to variation in the
target traits in opposite or same directions, respectively. The LDSC
intercept for the genetic covariance provides evidence about sample
overlap across two traits. SNPs (MAF > 0.01) found in the HapMap3
EUR population were used to calculate LD scores. We used the false
discovery rate29 to correct for multiple testing (n = 66 tests; q < 0.05).
Finally, post hoc analyses examined whether significant differences
between two rgs existed, using the jackknife procedure implemented
through LDSC.17
We used GNOVA30 to stratify significant rgs between the eating
disorder- and substance-use-related phenotypes into both tissue-
specific (for seven broadly defined tissue classes: brain, cardiovascular,
epithelial, gastrointestinal, immune-related, muscular, and “other”) and
nontissue-specific functional regions of the genome. GenoCanyon31
and GenoSkyline32,33 annotation methods, which integrate trans-
criptomic and epigenomic data from ENCODE34 and the Roadmap
Epigenomics Project,35 were used to define functional regions of the
genome.
Finally, for significant rgs detected in LDSC, multitrait-based con-
ditional and joint analysis using GWAS summary data (mtCOJO)36
was used to condition both input GWAS (eg, AN and AUD) for
variants associated with major depressive disorder37 at P < 5 ×10−7
and schizophrenia38 at P <5 ×10−8. Because fewer genome-wide
significant SNPs were identified for major depressive disorder
than schizophrenia, we chose a more lenient P value threshold for
major depressive disorder to capture a comparable number of SNPs.
LDSC was used to compute rgs using the resulting genome-wide sum-
mary statistics for each trait after separately adjusting for major
depressive disorder or schizophrenia variants to examine whether
conditioning on either disorder would affect the observed genetic
relationships.
3 | RESULTS
The overall SNP-based heritability for the eating disorder phenotypes
ranged from 0.20 to 0.39, whereas the corresponding heritabilities for
the substance-use-related phenotypes ranged from 0.03 to 0.35
(Table S1). Figure 1 and Table S1 show the genetic correlations (rgs)
between all four eating disorder phenotypes and eight substance-use-
related phenotypes. Broadly speaking, there were significant rgs
across substance-use-related phenotypes, ranging from 0.21 (AUD
and cigarettes per day) to 0.70 (drinks per week and AUD). Cannabis
initiation risk was not significantly genetically correlated with ciga-
rettes per day or nicotine dependence. For the remaining results, we
focus on previously unexplored associations of interest in this study—
correlations between eating disorder- and substance-use-related phe-
notypes. For these associations, the genetic covariance intercepts
ranged from −0.03 (standard error [SE] = 0.01; AN and cannabis initia-
tion) to 0.01 (SE = 0.01; AN and cannabis use disorder), indicating
some sample overlap (or low-level confounding) existed,39 although
the LDSC approach parses this overlap from the rg estimation.
Significant positive rgs were observed for alcohol- and cannabis
use-related phenotypes. First, the rg was significant between AN and
AUD (rg = 0.18; SE = 0.05; q = 0.0006) but not between AN and drinks
per week (rg = 0.01; SE = 0.03; q = 0.91), suggesting that genetic
factors that increase risk for AN also increase risk for AUD, but little
evidence exists for shared genetic risk between AN and typical
alcohol consumption. These two correlations significantly differed
from each other (z-score = 3.51, P = 0.0005). Intriguingly, there was a
significant difference in rgs for AN and AUD versus AN without binge
eating and AUD (z-score = 2.28, P = 0.02) but not for AN and AUD
versus AN with binge eating and AUD (z-score = 0.23, P = 0.82). The
genetic covariance estimates between AN and AUD were significant
in both functional (corrected ρg = 0.01; corrected r = 0.23; corrected q
= 0.007) and nonfunctional categories (corrected ρg = 0.01; corrected
r = 0.19; corrected q = 0.002; Table S2) but not in any specific tissue
TABLE 1 Eating disorder-related phenotype descriptions
Phenotype Definitions
Anorexia nervosa
(AN)a
Diagnostic criteria included the following:
1. Body mass index less than minimally expected
2. Intense fear of gaining weight
3. Weight or shape disturbance, undue influence
of weight or shape, or denial of the
seriousness of the disorder
AN with binge
eatingb
Individuals with AN who also engaged in
binge-eating episodes, defined as eating a
large amount of food in a short period of time
while having a sense of loss of control over
the eating episode.
AN without binge
eatingb
Individuals with AN who did not engage in
binge-eating episodes.
Bulimia nervosa
(BN)c factor
Derived from a factor analysis that included the
following items:
1. Reporting self-induced vomiting to control
body weight
2. Reporting suffering from or being treated for
binge eating
3. Reporting suffering from or being treated for
bulimia
aA fourth diagnostic criterion for AN includes amenorrhea. However,
amenorrhea was excluded as a required criterion for cases in the
Psychiatric Genomics Consortium datasets because it is no longer a
diagnostic criterion in the DSM-5.
bThe DSM and ICD include two subtypes of anorexia nervosa (AN)—a
binge-eating/purging subtype and a restricting subtype. Although it would
have been ideal to examine differences between the AN
binge-eating/purging subtype and AN restricting subtype, this was not
possible with current Psychiatric Genomics Consortium data. However,
there was sufficient information about presence or absence of binge
eating, which resulted in creating the AN with binge-eating and AN
without binge-eating subtypes.
cBulimia nervosa is defined as (a) recurrent episodes of binge eating, (b)
recurrent inappropriate compensatory behaviors (eg, self-induced
vomiting or laxative use) to prevent weight gain, (c) the binge eating and
inappropriate compensatory behaviors occurring an average of twice a
week for 3 mo, (d) having undue influence of body weight and shape, and
(e) disturbance not occurring during AN.
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type. No significant association between the bulimia nervosa factor
score, which included items pertaining to both binge eating and com-
pensatory behaviors, and either alcohol-use-related phenotype was
observed.
Second, the significant rg between AN and cannabis initiation was
0.23 (SE = 0.04, q < 0.0001) and the significant rg between AN with
binge eating and cannabis initiation was 0.27 (SE = 0.08, q = 0.0017),
indicating that genetic factors that increase the risk for AN may also
increase risk for cannabis initiation. However, cannabis initiation
was not significantly correlated with the bulimia nervosa factor score
(rg = 0.15, SE = 0.18, q = 0.57) or with AN without binge eating (rg =
0.10, SE = 0.08, q = 0.31). No significant associations were observed
between any eating disorder phenotype and cannabis use disorder (rgs
= −0.08-0.23; SEs = 0.01; qs < 0.57). Post hoc analyses revealed sig-
nificant differences in the rgs for AN and cannabis initiation versus AN
and cannabis use disorder (z-score = 2.70, P = 0.01). However, the rg
between AN with binge eating and cannabis initiation, while signifi-
cant, was statistically different from the rg between AN with
binge eating and cannabis use disorder. The genetic covariance esti-
mate between AN with binge eating and cannabis initiation was signif-
icant in both functional (corrected ρg = 0.01; corrected r = 0.60;
corrected q < 0.0001) and nonfunctional categories (corrected ρg =
0.01; corrected r = 0.30; corrected q = 0.004; Table S3) but not in any
specific tissue type. The genetic covariance estimate between AN
without binge eating and cannabis initiation was only significant in
TABLE 2 Details of samples included in analyses
Study Sample/Consortium Phenotype(s) Definition
Sample Size
(cases/controls if
binary)
Number of SNPs in
Summary Statistics
File
Eating disorder phenotype
Watson et
al (2019)
PGC-ED 1. Anorexia nervosa DSM-III-R, DSM-IV, ICD-8, ICD-9,
ICD-10, or self-reported
anorexia nervosa
16 992/55 525 8 219 102
2. Anorexia nervosa
with binge eating
2381/10 249 8 982 440
3. Anorexia nervosa
without binge eating
2262/10 254 8 671 192
Wade et al
(2013)
Australian Twin
Registry
Bulimia nervosa factor Eating Disorder Examination 151/2291 6 150 213
Substance use-related phenotype
Kranzler et
al (2019)
MVP Alcohol use disorder ICD-9 or ICD-10 34 658/167 346 6 895 251
Walters et
al (2018)
PGC-SUD Alcohol dependence DSM-IV 8485/20 272 9 271 145
Liu et al
(2019)
GSCAN 1. Drinks per weeka Average number of drinks each
week
537 349 11 916 707
2. Smoking initiation Ever vs never regular smoker 311 629/321 173 11 733 344
3. Current smokingc Current vs former smokers 92 573/220 248 12 197 133
4. Cigarettes per daya Average number of cigarettes
smoked per day
263 954 12 003 613
Hancock
et al
(2017)
14 samples Nicotine dependenceb Mild (FTND score 0-3)Moderate
(FTND score 4-6)Sever (FTND
score 7-10)
14 184 (Mild) 10 622 668
9206 (Moderate)
5287 (Severe)
Pasman et
al (2018)
ICC UK Biobank Cannabis initiation Lifetime cannabis use 43 380/118 702 11 733 371
Demontis
et al
(2019)
iPSYCH Cannabis use disorder ICD-10 2387/48 985 8 969 939
Abbreviations: DSM, Diagnostic and Statistical Manual; FTND, Fagerström Test of Nicotine Dependence; GSCAN, GWAS & Sequencing Consortium of
Alcohol and Nicotine use; ICC, International Cannabis Consortium; ICD, International Classification of Diseases; iPSYCH, Lundbeck Foundation Initiative
for Integrative Psychiatric Research; MVP, Million Veteran Program; PGC-ED, Eating Disorders Working Group of the Psychiatric Genomics Consortium;
PGC-SUD, Substance Use Disorders Working Group of the Psychiatric Genomics Consortium; SNPs, single nucleotide polymorphisms.
aTreated as a continuous phenotype.
bTreated as an ordinal phenotype.
cIn Lui et al (2019), the phenotype is labeled as “smoking cessation.” It was renamed as “current smoking” to reflect the coding scheme and for ease in
comparing across all smoking phenotypes.
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nonfunctional categories (corrected ρg = 0.01; corrected r = 0.27;
corrected q = 0.004; Table S4).
Conversely, for smoking phenotypes, significant correlations were
only observed for the AN without binge eating subtype. Smoking initi-
ation (rg = −0.21, SE = 0.06, q = 0.0006), current smoking (referred to
as smoking cessation in Liu et al20)* (rg = −0.19, SE = 0.08, q = 0.03),
and cigarettes per day (rg = −0.23, SE = 0.07, q = 0.003) were signifi-
cantly and negatively associated with AN without binge eating.
Although the correlation between nicotine dependence and AN
without binge eating was in the same direction as the other smoking
phenotypes, it was not significant (rg = −0.22, SE = 0.12, q = 0.14).
The rgs for AN diagnosis and each of the three nondiagnostic smoking
traits versus AN without binge eating and these same smoking traits
all differed significantly from each other (z-scores ranged from −3.22
to −2.11; P values < 0.04). The genetic covariance estimate between
AN without binge eating and smoking initiation was only significant in
the nonfunctional category (corrected ρg = −0.01; corrected r =
−0.17; corrected q = 0.007; Table S5). For AN without binge eating
and current smoking, the genetic covariance estimate was significant
in both functional (corrected ρg = −0.01; corrected r = −0.32;
corrected q = 0.01) and nonfunctional categories (corrected ρg =
−0.01; corrected r = −0.21; corrected q = 0.03; Table S6). Finally, the
genetic covariance estimate between AN without binge eating and
cigarettes per day was only significant in the nonfunctional category
(corrected ρg = −0.02; corrected r = −0.35; corrected q = 0.003;
Table S7).
After conditioning the AN and AUD GWAS summary statistics for
loci associated with major depressive disorder, the positive rg between
AN and AUD was attenuated (rg = 0.07; SE = 0.05, q = 0.125;
Table S8) and significantly lower than the unadjusted rg (z-score =
2.48, P = 0.01). In contrast, after conditioning the AN with binge eat-
ing and cannabis initiation GWAS for major depressive disorder, the
resulting rg was marginally smaller but remained significant after cor-
rection for multiple tests (rg = 0.21, SE = 0.08, q = 0.016). After condi-
tioning for the major depressive disorder GWAS, rgs between AN
without binge eating and smoking initiation, current smoking, and ciga-
rettes per day remained significant and modestly increased in magni-
tude (rgs = −0.27 to −0.31; SEs = 0.05 to 0.09; qs < 0.0009). All rgs
*In Liu et al (2019), the phenotype is noted as “smoking cessation,” where current smokers
were coded as 2 and former smokers were coded as 1. Because the comparison group is
“current smokers,” we have renamed this phenotype as “current smoking” for clarification
and ease of interpretation across all smoking phenotypes.
F IGURE 1 Genetic
correlations between eating
disorder subtypes and substance-
use-related phenotypes. Note. #
indicates known or potential
sample overlap with UK Biobank,
and & indicates known sample
overlap with iPSYCH. Starred
values denote significant genetic
correlations after correcting for
multiple comparisons using False
Discovery Rate (n tests = 66; q <
0.05)
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remained significant after conditioning the AN and substance-use-
related phenotypes for schizophrenia (rgs = −0.20 to 0.27; SEs = 0.04
to 0.08; qs < 0.03; Table S9).
4 | DISCUSSION
Using existing GWAS data, we investigated genetic associations
between liabilities to four eating disorder- and eight substance-use-
related phenotypes spanning initiation and typical use to substance
use disorder. We found differential patterns of association between
AN with and without binge eating and substance-use-related traits,
which may point toward substance-specific genetic relationships.
Additionally, there may be some degree of symptom overlap contrib-
uting to these associations.
Three main patterns emerged. First, in line with prior twin studies,
we observed a positive genetic correlation (rg) between problem alco-
hol use (ie, AUD) and AN diagnosis. Second, we observed positive, sig-
nificant rgs between cannabis initiation and AN diagnosis, as well as
cannabis initiation and the AN with binge eating subtype. This is a
novel finding not previously examined in twin research. The positive
genetic associations suggest that some genetic loci may be influencing
these traits in the same direction. Finally, negative rgs emerged
between the three nondiagnostic smoking phenotypes and AN with-
out binge eating but not with the other three eating disorder pheno-
types. These negative rgs indicate that some of the loci influencing
liability to these eating disorder and smoking phenotypes might be
shared but are affecting the liability to these traits in opposite direc-
tions. Indeed, rgs cannot identify specific loci or underlying mecha-
nisms that contribute to the shared risk. Nevertheless, the results
provide initial evidence for differential genetic associations between
the liability to varying eating disorder- and substance-use-related
phenotypes.
Based on findings from twin studies, we hypothesized that (a) the
strongest SNP-based rg would be between eating disorder pheno-
types that have binge eating as a core symptom and alcohol use phe-
notypes and (b) a significant positive rg between eating disorder
phenotypes with binge eating as a key symptom and AUD would
emerge. In line with these hypotheses, we found a significant genetic
association between AUD and AN diagnosis but not between typical
alcohol consumption (ie, drinks per week) and AN. No twin study has
examined genetic associations between AN and alcohol-use-related
phenotypes, and previous studies21,26 using LDSC have not reported
significant rgs between these traits. That we found a significant associ-
ation most likely reflects the larger AN sample size in our study (from
3495 cases and 10 982 controls to 16 992 cases and 55 525 controls),
as well as combining two large existing GWAS of AUD, emphasizing
the importance of increasing sample sizes for GWAS.
Importantly, the rgs between the eating disorder- and substance-
use-related phenotypes were robust to conditioning on schizophrenia
loci. However, the rg between AN and AUD was not robust to the
adjustment for major depressive disorder-associated variants. Major
depressive disorder is among the most prominent comorbidities in
individuals with AN and AUD,40 and GWAS for both traits document
strong rgs between major depressive disorder and these disor-
ders.19,21,26 Our results indicate that the three disorders share genetic
underpinnings. We cannot discount the possibility of a genetic rela-
tionship between AN and AUD that is distinct from major depressive
disorder; however, much larger sample sizes may be required to
detect such an association.
Intriguingly, although we did not detect a significant rg for AN
with binge eating with AUD, the point estimate for the rg between
AUD and AN with binge eating was similar to that for AUD and AN
diagnosis (0.17 vs 0.18, respectively) and higher than that for AUD
and AN without binge eating (0.01). Sample sizes for these AN sub-
types were smaller than for AN diagnosis; however, the two subtypes
included approximately equal numbers of cases and controls. Indeed,
binge eating was assessed in such a way that we were unable to tease
apart purging behaviors, and AN diagnosis is heterogenous even
within subtypes. Therefore, binge eating may be one plausible key
component of the observed genetic association. For example, binge
eating has been shown to activate brain reward circuitry in a similar
manner to substances,41,42 and administration of naltrexone, an opioid
antagonist approved by the US Food and Drug Administration for the
treatment of AUD,43 has been shown to reduce the frequency of
binge eating episodes among individuals with an eating disorder.44,45
We did not detect a significant rg with the bulimia nervosa factor
score, although that GWAS was relatively underpowered. Thus, our
findings highlight the importance of expanding GWAS to include
bulimia nervosa and binge-eating disorder, where a core symptom of
both disorders is binge eating, to elucidate whether binge eating is a
critical eating disorder symptom in the comorbidity with AUD and to
home in on relevant shared mechanisms.
The significant genetic associations between cannabis initiation
and AN are novel, yet consistent with the negative genetic
association between cannabis use and body mass index, and with
observational25 and experimental46,47 studies regarding the role of
endocannabinoids in appetite regulation, energy expenditure, stress,
and reward. One of the principal psychoactive agents of cannabis,
delta-9-tetrahydrocannabinol (THC), a partial agonist of the endoge-
nous cannabinoid 1 (CB1) receptor, is presumed to be orexigenic and
may acutely increase appetite and food intake, contributing to its
potential role as an appetite stimulant in patients with an anorexia or
cachexia syndrome48 due to a disease (eg, HIV or AIDS) or in
response to treatment (eg, chemotherapy). An antagonist of the CB1
receptor was previously tested as a highly promising anti-obesity
medication (Rimonabant, SR141716), which is particularly relevant
because some genes may influence AN and obesity in opposite direc-
tions.21 Further, the endocannabinoid anandamide has been shown
to be elevated in individuals with acute AN,49 indicating disruption in
food-related reward and eating behavior regulation. Animal and
human studies have also provided initial evidence for the therapeutic
effectiveness of cannabinoid agonists in treating eating disorders.50,51
It is also likely that individuals with high genetic liability to AN are
less likely to experiment with a substance that has a documented
hyperphagia component. Thus, there is evidence of a complex
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biological relationship between cannabis use and eating disorders, as
well as body mass index.
Finally, the significant negative rgs between three tobacco-
smoking phenotypes—smoking initiation, current smoking, and ciga-
rettes per day—and AN without binge eating are intriguing,
suggesting that AN without binge eating and tobacco-smoking
behaviors are alternate expressions of shared mechanisms. Pheno-
typic studies are inconsistent about the association between the
restricting subtype of AN and smoking. Some studies suggest that
individuals with restricting AN have a higher prevalence of various
smoking phenotypes than controls,5 whereas other studies indicate
no significant difference between the two groups.6 A recent meta-
analysis did not find differences in the odds of lifetime smoking
between individuals with AN and healthy controls,3 yet the authors
did not assess differences by AN subtype. Individuals with AN may
smoke as a way to control or lose weight,52 and temporary weight
gain does occur with smoking cessation.53 However, a positive phe-
notypic correlation need not be accompanied by a rg in the same
direction (or genetic contributors to the phenotypic association at
all). Still, there is plausible support for the negative rg. Although not
significant, a negative rg between smoking and AN has been
reported.18,21 Notably, our study includes individuals from these
earlier reports and extends findings by including larger sample sizes
for both AN and smoking phenotypes. Unfortunately, there are no
twin studies of AN or AN-like traits and smoking with which to
compare findings.
One explanation for the negative genetic association is that it is
due to a third, underlying variable influencing both AN without binge
eating and smoking. We tested for the potential role of variants asso-
ciated with major depressive disorder and schizophrenia and found
the rgs to be robust to those adjustments. In the largest GWAS of
smoking phenotypes, positive rgs were also observed between
smoking initiation and cigarettes per day with multiple car-
diometabolic traits, including type 2 diabetes and fasting glucose.20
These same metabolic traits were negatively genetically correlated
with AN.21,54 Thus, the patterns of rgs might point to metabolic, rather
than psychiatric, factors in influencing the apparent genetic associa-
tion between smoking phenotypes and AN. However, the associations
could also reflect adoption of unhealthy lifestyles that promote obe-
sity and are correlated with smoking. In addition, the rgs between
smoking and body mass index, as well as AN and body mass index,
may reflect underlying disinhibitory pathways, as variants associated
with body mass index show enrichment in the central nervous
system.55 The current approach is not designed to disentangle these
putative etiological mechanisms, but our findings do encourage care-
ful study of the specific relationships between eating and substance
use disorders.
Substance use and substance use disorders are partially distinct,
and although excessive substance use is a necessary component of
substance use disorders, the latter is associated with psychological
and physiological impairment related to excess use and aspects of loss
of control over the behavior. Consistent with our findings for alcohol,
accumulating evidence suggests that genetic liability to other
psychiatric traits (eg, schizophrenia) is strongly correlated with liability
to substance use disorders (eg, AUD) but not substance use (eg, alco-
hol consumption).19-21 Genetic liability to alcohol use has also been
correlated with liabilities to psychiatric disorders (eg, major depressive
disorder) in opposite directions depending on level of involvement.19
However, we did not find similar elevations in rgs when contrasting
ever smoking and nicotine dependence nor comparing cannabis initia-
tion to cannabis use disorder. It is possible that the lack of genetic
overlap between AN and nicotine dependence, as well as AN and can-
nabis use disorder, is related to the relatively modest sample size of
those discovery GWAS. A similar non-significant rg was noted for
AUD when the Walters et al26 alcohol dependence GWAS was used
as the sole source of summary statistics for problem drinking in the
current study. Several other explanations for this divergence in
findings exist. For instance, for tobacco, the highly addictive nature of
nicotine may result in convergence in genomic effects on earlier and
later stages of smoking (ie, a much larger proportion of those who
ever smoke become dependent compared with the proportion of
those who drink alcohol and develop AUD). For cannabis, given its
lower addictive potential, we might have expected stronger associa-
tions with cannabis use disorder than with cannabis initiation. In addi-
tion to the considerably smaller sample size of the cannabis use
disorder GWAS, the association with cannabis initiation could also be
attributed to the small number of cohorts in that discovery GWAS
that included individuals with a high likelihood of cannabis use disor-
der. It is also possible that the relationship between AN and cannabis
use is distinct and that earlier but not later stages of cannabis use are
genetically related to liability to AN. Future studies should consider
the multistage nature of substance use and misuse when examining
cross-trait correlations.
This is the largest and most comprehensive assessment of
shared genetic risk between eating disorder- and substance-use-
related phenotypes, using existing GWAS data from large cohorts
(up to ~537 000 individuals per phenotype). We were able to sepa-
rately assess approximate AN subtypes (ie, with binge eating vs with-
out binge eating) to evaluate the extent to which binge eating, in
the context of AN, may share genetic risk with substance-use-
related phenotypes. Using these large datasets—many of which are
publicly available—allows for the rapid development of scientific
knowledge regarding the underlying etiology of psychiatric disorder
and substance use comorbidity. Nevertheless, some limitations exist.
First, sample sizes for the bulimia nervosa factor score and cannabis
use disorder GWAS were relatively small compared with the other
GWAS, resulting in large standard errors and low power. Second, we
were unable to uniformly examine sex differences in these
rgs. Because the prevalence of eating disorders is higher in women
than men and the prevalence of substance use disorders is higher in
men than women,40 it will be important to explore possible sex dif-
ferences in genetic associations as the GWAS data become available.
Notably, we previously did not find evidence for sex differences in
the rg between binge eating and problem alcohol use.
56 Third, even
though we did not detect significant rgs for all pairs of traits, it is
possible that local genetic associations exist for some of these trait
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pairs. Such local correlations, for instance, in certain chromosomal
regions but not others, particularly when in opposing directions (eg,
a positive local correlation at one chromosomal location and a nega-
tive local correlation at another) might dilute the overall rg estimate.
Although such a systematic evaluation of each pair of traits is
beyond the scope of this report, we did note some support for
enrichment of the aggregated genetic covariance in both functional
and nonfunctional genomic regions for several of the significant
rgs. Finally, SNP coverage was limited in the earlier GWAS of the
bulimia nervosa factor score because that study used older
genotyping platforms and imputation panels that included fewer
SNPs than current imputation panels. The Eating Disorders and
Substance Use Disorders Working Groups of the Psychiatric
Genomics Consortium are continuously adding samples and releasing
data freezes with incrementally larger sample sizes, while collecting
information on multiple substances (eg, opioids). In coming years,
the statistical power is expected to increase for AN (including the
with and without binge eating subtypes), bulimia nervosa, and binge-
eating disorder, as well as AUD, nicotine dependence, and cannabis
use disorder, from within and outside the Psychiatric Genomics Con-
sortium. This will allow for a more refined assessment of specific
eating disorder symptoms, including binge eating, in relation to
substance-use-related phenotypes.
In conclusion, findings from this study suggest that the shared
sources of variation in liabilities to eating disorder- and substance-
use-related phenotypes are not consistent across traits or levels of
substance involvement, extending results from twin studies to a
genome-wide SNP approach. Despite the typically high co-
occurrence of alcohol, tobacco, and cannabis use and their genetic
overlap,25 the differential patterns seen between the eating
disorder- and substance-use-related phenotypes highlight the
uniqueness and complexity of their shared etiology. Potential clini-
cal implications include watching for the emergence of symptoms
of one disorder (eg, AN) while being treated for the other behavior
(eg, AUD) and understanding that, for example, women with AN
who use nicotine may not be able to quit successfully both because
they are afraid of gaining weight and they have high genetic sus-
ceptibility for smoking via the shared genetic risk between AN and
smoking-related traits. Additional research using contemporary
genomic methods, such as cross-disorder association studies, could
identify the specific loci contributing to this comorbidity. Future
research that combines genome-wide data with measured environ-
mental constructs, such as trauma,9 that may increase risk for this
comorbidity could enhance the prediction, prevention, and treat-
ment of co-occurring eating disorder- and substance-use-related
traits.
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